A pilot project on the future of work at the FDA could lead to reduced office space requirements and improve recruitment and retention, officials say.
In-person work expectations at the US Food and Drug Administration could significantly change post-pandemic as the agency tries to become a more attractive destination for scientific and regulatory talent.
Agency officials recently launched a pilot program to figure out the “new normal” for work, said James Sigg, FDA deputy...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
